HIGH THROUGHPUT DRUG SCREENING FACILITY FOR NEURODEGENERATIVE DISEASE: REQUEST
FOR INFORMATION (RFI)
Release Date: January 11, 2001
NOTICE: NOT-NS-01-005
National Institute of Neurological Disorders and Stroke
The National Institute for Neurological Disorders and Stroke (NINDS) is
considering issuing a contract for high throughput drug screening (HTS) of new
chemical entities for the treatment of neurodegenerative diseases. The institute
is attempting to identify competent sources to adapt in vitro assays to HTS
formats and screen chemical libraries for biological activity in these assays.
Background
The NINDS wishes to facilitate the use of high throughput drug screening (HTS)
to identify compounds for the treatment of neurodegenerative diseases and for
investigating mechanisms of these diseases. Many investigators have developed in
vitro assays that reflect neurodegenerative disease processes. The Institute is
considering using a contract mechanism to have these assays adapted to HTS
formats, and then used to screen diverse chemical libraries.
The results of the screening are intended to benefit both drug development and
pre-clinical research. Compounds that are active in the assays will be made
available to investigators for use as research tools. Assays that prove
practical for this approach will be made generally available to encourage
further drug development.
Information Requested
Information in the following areas will aid in the design of solicitations for a
HTS facility. We ask that interested organizations identify critical criteria to
include in these solicitations and describe their capabilities to meet these
criteria. Information presented need not be limited to these areas.
1. Modification and Testing of Assays for HTS:
a. Describe your capabilities to modify experimental in vitro assays to produce
assay protocols suitable for HTS. Assays developed by the source may be listed,
as well as technical capabilities of personnel and the capacity of
available facilities.
b. Describe the criteria by which you would judge the usefulness of an assay for
drug development and by which you would prioritize and coordinate the screening
of multiple assays.
c. Describe your capabilities for data analysis, including structure-activity
analysis.
2. Chemical Libraries:
a. Describe the chemical libraries that would be purchased and screened under
the potential contract, including costs.
b. Describe how active compounds would be made available to investigators,
including production costs.
3. Personnel:
Describe the personnel who would be required to modify, screen and analyze one
assay. Include an estimate for the level of effort of each.
This Request for Information (RFI) is for information and planning purposes only
and shall not be construed as a solicitation or as an obligation on the part of
the Government. The Government does not intend to award a contract on the basis
of responses nor otherwise pay for the preparation of any information submitted
or the Government’s use of such information. Acknowledgment of receipt of
responses will not be made, nor will respondents be notified of the Government’s
evaluation of the information received. However, should such a requirement
materialize, no basis for claims against the Government shall arise as a result
of a response to this request for information or the Government’s use of such
information as either part of our evaluation process or in developing
specifications for any subsequent requirement. Responses will be held in a
confidential manner. Any proprietary information should be so marked.
All respondents are asked to indicate the type and size of your business or
organization, e.g., Large Business, Small Business, Hubzone Small Business,
Small Disadvantaged Business, Women-Owned Business, 8(a), Historically Black
College or University/Minority Institution (HBCU/MI), educational institution,
profit/non-profit hospital, or other non-profit organization.
Responses should be identified with RFI No. NS-01-005, and are due by February
1, 2001. Please submit three (3) copies of your response, to Patricia S. Denney,
Contracting Officer, Contracts Management Branch, National Institute of
Neurological Disorders and Stroke, NIH, 6001 Executive Boulevard, Room 3282,
Bethesda, MD 20892-9531 (For Fedex or courier, use: Rockville, MD 20852). Email
responses will also be accepted at pd22n@nih.gov.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|